These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29429550)

  • 1. Imatinib: A New Tool for the Management of Chronic Sclerodermatous Graft-Vs-Host Disease.
    Ferrándiz-Pulido C
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):200-201. PubMed ID: 29429550
    [No Abstract]   [Full Text] [Related]  

  • 2. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
    de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
    Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
    [No Abstract]   [Full Text] [Related]  

  • 4. Localized edema with sclerodermatous evolution: a possible form of skin chronic graft-versus-host disease associated with endothelial activation.
    Tardieu M; Rybojad M; Peffault de Latour R; Robin M; de Masson A; Xhaard A; Le Buanec H; Parquet N; Sicre de Fontbrune F; Bergeron A; Scieux C; Dessirier V; Bensussan A; Bagot M; Socié G; Bouaziz JD
    Blood; 2013 Jul; 122(3):463-5. PubMed ID: 23869081
    [No Abstract]   [Full Text] [Related]  

  • 5. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
    Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
    PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
    Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
    Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib for sclerodermatous graft-versus-host disease in lung transplantation.
    Zhang J; Chen F; Ueki T; Date H
    Interact Cardiovasc Thorac Surg; 2015 Aug; 21(2):260-2. PubMed ID: 25972597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerodermatous changes of chronic graft-versus-host-disease treated with puva.
    Woscoff A; Ruíz Lascano A; De Pablo AB; Robinson A
    Int J Dermatol; 1996 Sep; 35(9):656-8. PubMed ID: 8876297
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD.
    George L; George B; Gottlieb DJ; Hertzberg M; Fernandez-Peñas P
    Bone Marrow Transplant; 2012 May; 47(5):737-8. PubMed ID: 21785472
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].
    Pédailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M
    Presse Med; 1993 Jan 2-16; 22(1):37. PubMed ID: 8469665
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.
    Hurabielle C; Sicre de Fontbrune F; Moins-Teisserenc H; Robin M; Jachiet M; Coman T; Dhedin N; Cassius C; Chasset F; de Masson A; Michonneau D; Bagot M; Bergeron A; Socié G; Peffault de Latour R; Bouaziz JD
    Br J Dermatol; 2017 Nov; 177(5):e206-e208. PubMed ID: 28422274
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions.
    Phipps C; Lupo-Stanghellini MT; Flowers ME
    Bone Marrow Transplant; 2014 Feb; 49(2):315-6. PubMed ID: 24076547
    [No Abstract]   [Full Text] [Related]  

  • 13. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
    Tolland JP; Devereux C; Jones FC; Bingham EA
    Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pediatric Case of Sclerodermatous Graft-Versus-Host Disease Responsive to Ultraviolet A1 Phototherapy.
    Lazzeri L; Tripo L; Pescitelli L; Ricceri F; Prignano F
    Pediatr Dermatol; 2016; 33(2):e99-102. PubMed ID: 26871550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment.
    Weiss M; de Masson A; Robin M; Peffault de Latour R; Bagot M; Socié G; Bouaziz JD
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):e791-e793. PubMed ID: 32329912
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide.
    Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
    J Invest Dermatol; 2016 Nov; 136(11):2158-2167. PubMed ID: 27424318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease.
    Kim JB; Liakopoulou E; Watson JS
    J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1235-8. PubMed ID: 17509955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib treatment of therapy resistant generalized deep morphea.
    Alcántara-Reifs CM; Garnacho-Saucedo GM; Salido-Vallejo R; de la Corte-Sánchez S; García-Nieto AV
    Dermatol Ther; 2015; 28(5):271-3. PubMed ID: 26032018
    [No Abstract]   [Full Text] [Related]  

  • 19. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
    Lazar J; Poonawalla T; Teng JM
    Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
    Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.